Evidence used
- No CISA KEV confirmation is currently recorded.
- EPSS is 0.49% for the current model date.
BlackTreeCVE IntelligenceInsulet · Omnipod Insulin Management System
High technical severity; prioritise exposed affected systems while verifying vendor guidance.
High technical severity; prioritise exposed affected systems while verifying vendor guidance.
Fix not verifiedInsulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.
Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.
The product does not restrict or incorrectly restricts access to a resource from an unauthorized actor.
An attacker operating through local access may attempt exploitation without authentication or user interaction. If successful, the issue may cause the confidentiality, integrity or availability impact described by the vendor.
Insulet Omnipod Insulin Management System insulin pump product ID 19191 and 40160 is designed to communicate using a wireless RF with an Insulet manufactured Personal Diabetes Manager device. This wireless RF communication protocol does not properly implement authentication or authorization. An attacker with access to one of the affected insulin pump models may be able to modify and/or intercept data. This vulnerability could also allow attackers to change pump settings and control insulin delivery.
The product does not restrict or incorrectly restricts access to a resource from an unauthorized actor.
An attacker operating through local access may attempt exploitation without authentication or user interaction. If successful, the issue may cause the confidentiality, integrity or availability impact described by the vendor.
CVSS severity, EPSS forecast probability, public exploit material and CISA-confirmed exploitation are separate signals.
No CISA KEV match was present at the last successful refresh. This means no confirmation from that source, not proof of no exploitation.
No exploit-tagged reference or CISA SSVC proof-of-concept state is currently recorded. Research may still exist outside the structured feeds.
CWE-284: Improper Access Control. The product does not restrict or incorrectly restricts access to a resource from an unauthorized actor.
CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:LCommon Vulnerability Scoring System 3.1: the compact vector below is decoded into plain language.
Operational remediation based on structured source evidence.
Published 1 Dec 2021 · Last source change 4 Aug 2024, 11:06 UTC · CWE-284 · Improper Access Control
Core structured fields are present and their contributing authorities are shown above.
No material field changes have been recorded since change tracking began. Routine source refreshes and cosmetic edits are intentionally excluded.